Cargando…
Telisotuzumab vedotin with erlotinib in the treatment of non-small cell lung cancer: a well MET combination?
| Autores principales: | , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
AME Publishing Company
2023
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10483073/ https://www.ncbi.nlm.nih.gov/pubmed/37691875 http://dx.doi.org/10.21037/tlcr-23-288 |
| _version_ | 1785102299858731008 |
|---|---|
| author | Kujtan, Lara Subramanian, Janakiraman |
| author_facet | Kujtan, Lara Subramanian, Janakiraman |
| author_sort | Kujtan, Lara |
| collection | PubMed |
| description | |
| format | Online Article Text |
| id | pubmed-10483073 |
| institution | National Center for Biotechnology Information |
| language | English |
| publishDate | 2023 |
| publisher | AME Publishing Company |
| record_format | MEDLINE/PubMed |
| spelling | pubmed-104830732023-09-08 Telisotuzumab vedotin with erlotinib in the treatment of non-small cell lung cancer: a well MET combination? Kujtan, Lara Subramanian, Janakiraman Transl Lung Cancer Res Editorial Commentary AME Publishing Company 2023-07-28 2023-08-30 /pmc/articles/PMC10483073/ /pubmed/37691875 http://dx.doi.org/10.21037/tlcr-23-288 Text en 2023 Translational Lung Cancer Research. All rights reserved. https://creativecommons.org/licenses/by-nc-nd/4.0/Open Access Statement: This is an Open Access article distributed in accordance with the Creative Commons Attribution-NonCommercial-NoDerivs 4.0 International License (CC BY-NC-ND 4.0), which permits the non-commercial replication and distribution of the article with the strict proviso that no changes or edits are made and the original work is properly cited (including links to both the formal publication through the relevant DOI and the license). See: https://creativecommons.org/licenses/by-nc-nd/4.0 (https://creativecommons.org/licenses/by-nc-nd/4.0/) . |
| spellingShingle | Editorial Commentary Kujtan, Lara Subramanian, Janakiraman Telisotuzumab vedotin with erlotinib in the treatment of non-small cell lung cancer: a well MET combination? |
| title | Telisotuzumab vedotin with erlotinib in the treatment of non-small cell lung cancer: a well MET combination? |
| title_full | Telisotuzumab vedotin with erlotinib in the treatment of non-small cell lung cancer: a well MET combination? |
| title_fullStr | Telisotuzumab vedotin with erlotinib in the treatment of non-small cell lung cancer: a well MET combination? |
| title_full_unstemmed | Telisotuzumab vedotin with erlotinib in the treatment of non-small cell lung cancer: a well MET combination? |
| title_short | Telisotuzumab vedotin with erlotinib in the treatment of non-small cell lung cancer: a well MET combination? |
| title_sort | telisotuzumab vedotin with erlotinib in the treatment of non-small cell lung cancer: a well met combination? |
| topic | Editorial Commentary |
| url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10483073/ https://www.ncbi.nlm.nih.gov/pubmed/37691875 http://dx.doi.org/10.21037/tlcr-23-288 |
| work_keys_str_mv | AT kujtanlara telisotuzumabvedotinwitherlotinibinthetreatmentofnonsmallcelllungcancerawellmetcombination AT subramanianjanakiraman telisotuzumabvedotinwitherlotinibinthetreatmentofnonsmallcelllungcancerawellmetcombination |